Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Additionally, APOE polymorphic alleles that characterize impaired cerebrovascular integrity function as primary genetic determinants of AD.
|
31815697 |
2020 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Associations between Aβ misfolding, APOE4, and other predictors with clinical AD, vascular dementia, and mixed dementia diagnoses were assessed.
|
31611055 |
2020 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
One model was run for each AD risk factor, including: objectively-defined subtle cognitive decline (Obj-SCD), and genetic susceptibility [apolipoprotein E ε4 (APOE ε4) as well as cerebrospinal fluid β-amyloid (Aβ), total tau (tau), and hyperphosphorylated tau (p-tau).
|
31305320 |
2020 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our work suggests that CA may be a potential approach to attenuate the risk of ApoE4-associated AD.
|
31796678 |
2020 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The ɛ4 allele of apolipoprotein E (apoE4) is the most prevalent genetic risk factor for Alzheimer's disease.
|
31489583 |
2020 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Susceptibility to AD is likely the result of complex interactions of the ε2 and ε4 alleles with other polymorphisms in the APOE region, and these interactions differ across races/ethnicities corroborating differences in the adverse and beneficial effects of the ε4 and ε2 alleles.
|
31813627 |
2020 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
It has been reported that APOEɛ4, and not aggregated Aβ, contributes to glucose hypometabolism in pre-clinical stages of Alzheimer's disease (AD) pathology.
|
31796668 |
2020 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The lipid-binding protein apolipoprotein E (ApoE) has been found to interfere with Aβ amyloid formation and to exert a strong clinical impact to the pathology of AD.
|
31571352 |
2020 |
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Additionally, p-BTX-I alone increased the expression of apolipoprotein E (apoE) gene, associated with the proteolytic degradation of β-amyloid peptide aggregates, a hallmark of AD.
|
31654382 |
2020 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Analysis implied that APOE ε4 might affect CSF YKL-40 levels in MCI subjects, suggesting a crucial role of APOE ε4 in neuroinflammation in detecting individuals who might convert to AD from MCI and, thus, as an effective predictive factor.
|
31794792 |
2020 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study examined neuropsychological correlates of phonemic cueing benefit and the influential effects of AD severity, estimated premorbid intellectual functioning, and apolipoprotein E genotype status.
|
31030619 |
2020 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
[PROVISIONAL] The combined risk effect among BIN1, CLU and APOE genes in Alzheimer's disease.
|
31469155 |
2020 |
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
APOE ε4-specific associations of VEGF gene family expression with cognitive aging and Alzheimer's disease.
|
31791659 |
2020 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In addition, TADDZ corrected ASL MRI, with improved consistency, was shown to outperform conventional ASL MRI by differentiating the subtle CBF difference in Alzheimer's disease (AD) mice brains with different APOE genotypes.
|
31669538 |
2020 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The O-glycoprotein Apolipoprotein E (APOE), the strongest genetic risk factor for Alzheimer's disease, associates with lipoproteins.
|
31616924 |
2020 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In a whole-exome sequencing study of a family with probable AD-type dementia without pathogenic variants in known autosomal dominant dementia disease genes and negative for the apolipoprotein E (APOE) ε4 allele, we identified an extremely rare TREM2 coding variant, that is, a glycine-to-tryptophan substitution at amino acid position 145 (NM_018965.3:c.433G>T/p.[Gly145Trp]).
|
31464095 |
2020 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data indicated that the ApoE ε4 allele may also contribute to the pathogenesis of Alzheimer's disease through its effects on peripheral Aβ<sub>42</sub> and sLRP1 levels, but it needs to be further elucidated.
|
31350163 |
2020 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein E, lipoprotein(a), oxidized LDL (low density lipoprotein)'s and large LDL particles, as well as other proinflammatory lipids and stress hormones such as cortisol, have been recognized as key factors in amyloid plaque formation and aggravation of AD.
|
31595035 |
2020 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
An upcoming phase 3 trial with ALZ-801 in APOE4/4 homozygous patients with early AD will effectively test this amyloid oligomer hypothesis.
|
31706733 |
2020 |
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
To investigate the gene-environment interactions (GxE) between ApoE-ε4 and Cd exposure on cognition, we used a mouse model of Alzheimer's disease that expresses human ApoE-ε3 (ApoE3-KI (knock-in)) or ApoE-ε4 (ApoE4-KI).
|
31626305 |
2020 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that the underlying mechanism of APOE polymorphism modulations on EM function and AD susceptibility is genetically related to the neural degeneracy of EM function across APOE alleles.
|
29396739 |
2019 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein E (APOE) is a prominent genetic risk factor for Alzheimer's disease (AD) and a frequent target for associations with non-demented and cognitively impaired aging.
|
30873923 |
2019 |
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, we compared neuropathological features, tau haplotypes, apolipoprotein E (APOE) genotypes, and cognitive profiles in age-matched subjects with PART and AD pathology.
|
30465754 |
2019 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Compared to APOEɛ4 non-carriers, APOEɛ4 carriers showed the opposite trajectory of DMN connectivity across the AD spectrum.
|
31282419 |
2019 |
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
We hypothesize that APOE4 influences all the pathological hallmarks of AD and may sit at the interface between neurodegeneration, inflammation and the spread of pathologies through the brain.
|
30394574 |
2019 |